Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV - Hehlmann, Rüdiger; Müller, Martin Christian; Hanfstein, Benjamin; Fabarius, Alice; Schreiber, Annette; Proetel, Ulrike; Dengler, Jolanta; Saußele, Susanne (Journal of clinical oncology, 2014)
Gesehen am 23.06.2015